1 / 23

MERCK Site Visit Prep session Moshe Kelsen, Andrew Black, Nazli Fard November 13, 2008

Out line. Site Visit AgendaAbout MerckEarly HistoryKey ProductsResearch

issac
Download Presentation

MERCK Site Visit Prep session Moshe Kelsen, Andrew Black, Nazli Fard November 13, 2008

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. . MERCK Site Visit (Prep session) Moshe Kelsen, Andrew Black, Nazli Fard November 13, 2008

    2. Out line Site Visit Agenda About Merck Early History Key Products Research & Development Financials Vaccine Market Recent News

    3. Site Visit Agenda Date: Friday, Nov. 14th, 2008 Time: Plan on arriving at the site by 8:15am Location: One Merck Drive, Whitehouse Station NJ (Conference Room1A-40) Topic: “The Challenges and Opportunities of Careers in the Pharmaceutical Industry ”

    4. About Merck Merck is a global research-driven pharmaceutical company, established in 1891 Discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs Devotes extensive efforts to increase access to medicines through far-reaching program (donates Merck medicines and helps deliver them to the people who need them) Global Headquarters: Whitehouse Station, New Jersey 59,800 employees worldwide Manufacturing Divisions in 25 countries Generates revenues through three business divisions: Pharmaceuticals (91.6% of the total revenues during fiscal year 2006), Vaccines (7.7%) and ‘Other' (0.7%)

    5. Early History 1668: Frederic Jacob Merck opened a chemical firm in Darmstadt, Germany 1891: Establishment of a US branch 1904: First US factory opened (Rahway) 1933: First research lab opened 1940-50s: Merck researchers win 5 Nobel prizes Today, Merck is one of the seven largest pharmaceutical companies in the world both by capital and revenue

    6. Competitors Novartis Bristol-Myers Squibb Roche Eli Lilly Johnson & Johnson

    7. Cozaar Drug name: Losartan 2007 Sales: $ 3.35 billion Indications: Hypertension (High blood pressure), reducing the risk of stroke, preventing kidney damage in diabetics. Notes: Hyzaar is a combination product containing Cozaar and an older blood pressure medication called Hydrochlorothiazide. Cozaar sales figures include Hyzaar sales. Expected patent expiration 2010

    8. Fosamax Drug name: Alendronate 2007 Sales: $3.049 billion Indications: Osteoporosis (Strengthening bones) Notes: Fosamax is a once weekly tablet for strengthening bones. The first generic was approved earlier this year, so sales are expected to drop off. They are now focusing on Fosamax+D a combination product. The D is for Vitamin D which helps to deposit calcium in the bones and improve outcomes.

    9. Januvia Drug name: Sitagliptin 2007 Sales: $ 667 million Indications: Improves control of blood sugar levels in Type 2 diabetics. Notes: This is early days for Januvia and it should become a top selling product. Merck also markets a product called Janumet which combines the Januvia product with another sugar lowering drug called metformin. This drug was the first in its class.

    10. Singulair Drug name: Monteleukast 2007 Sales: $4.266 billion Indications: Prevention and management of asthma symptoms, Control of indoor and outdoor allergy symptoms Notes: This was Merck’s top selling product of 2007. It is a once daily tablet. Many patients and doctors like this product because it is a non-steroid based treatment for the prevention of asthma symptoms. Expected patent expiration in 2012

    11. Gardasil Human Papillomavirus Vaccine 2007 Sales: $1.48 billion Indications: Prevention of genital warts and cancers associated with HPV infection – cervical, vulvar and vaginal. Notes: Girls and women between the ages of 9 and 26 can receive the vaccine. Vaccination is a series of 3 injections at 0, 2 and 6 months.

    12. RotaTeq Rotavirus Vaccine 2007 Sales: $524 million Indications: Prevention of rotavirus gastroenteritis in infants and children.  Notes: This is an oral vaccine in ready to use liquid doses. It is a series of 3 doses starting at 6-12 weeks of age, and subsequent doses given 4-10 weeks apart. Adults are largely immune to rotavirus, but infants and children are most susceptible, and complications associated with infection can be serious.

    13. Other Products Producing Strong Revenues Zocor (Cholesterol tablets) Cosopt/Trusopt (Glaucoma eye drops) Vasotec/Vaseretic (Blood presure) Maxalt (Migraine treatment) ProQuad/M-M-R II/Varivax (MMR and Chickenpox vaccine)

    14. RESEARCH PIPELINE

    16. EMEND is a powerful medication that, when started before each cycle of chemotherapy, can help prevent the nausea and vomiting caused by chemotherapies that are likely to cause nausea and vomiting. Janumet- treatment for type two diabetes Isentress- treatment for HIV virus, 18 months ahead of schedule, from approval to market in 4 days

    17. KEY FINANCIALS Number of employees worldwide: 56,700 as of September 30th, 2008 Worldwide Sales:  $5.94 billion for the third quarter of 2008 (2% decline from previous year) Stock Ticker: MRK Stock Price: $28.92 EPS: 2.09 P/E: 13.84 Financial News: 2008 Global Restructuring Efforts Expected to Reduce Workforce by 12 Percent (7,200 positions); cumulative savings of $3.8 to $4.2 Billion expected from 2008 to 2013 and Pretax Costs of $1.6 Billion to $2.0 Billion Through 2011 Merck plans to continue its stock buyback program in 2008. As of Sept. 30, 2008, $2.6 billion remains under the current buyback authorizations approved by Merck’s Board of Directors. Largest-selling product:  Sales of SINGULAIR® were $1.0 billion in 3Q08

    19. Recent News ROTATEQ Oct. 10, 2008: Merck's ROTATEQ Receives WHO Pre-qualification WHO pre-qualification allows for expanded access to ROTATEQ and provides a greater opportunity to help protect millions of babies from rotavirus gastroenteritis http://www.fiercebiotech.com Oct. 25, 2008: Merck's ROTATEQ Substantially Reduced Rotavirus-related Hospitalizations and Emergency Room Visits Data are based on a review of health insurance claims data from approximately 61,000 infants in the U.S

    20. CANCIDAS Aug.  5, 2008: FDA has approved an expanded label for CANCIDAS This is the first and only echinocandin therapy approved in the United States for the treatment of pediatric patients aged 3 months to 17 years with indicated fungal infections The expanded label for CANCIDAS is based on data from five prospective clinical studies involving 171 pediatric patients Recent News

    21. GARDASIL Sept. 12, 2008: FDA Approved Merck's GARDASIL to Protect Against Two Additional Cancers Vaccine Now Indicated for Prevention of Vaginal and Vulvar Cancers in Girls and Women Ages 9 through 26 The approval is based on data from a combined analysis of three studies that demonstrated the efficacy and safety of GARDASIL in more than 15,000 patients. Recent News

    22. VIOXX July 17, 2008 : Recent News

    23. Nov.  8, 2008: Merck reaffirmed its commitment to discovering and developing novel treatments for a broad range of cardiovascular disorders This year marks the 50th anniversary of the launch of the Company's first major medicine for cardiovascular disease. Recent News

    24. References Patent expiration information http://online.wsj.com/public/resources/documents/info-pharma0712-sort.html 2007 Product Sales Data – 10-K filing http://www.merck.com/finance/sec/sec_filings.html

More Related